• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

前列宁胶囊通过抑制表皮生长因子/信号转导和转录激活因子3信号通路治疗良性前列腺增生。

Qianliening capsule treats benign prostatic hyperplasia via suppression of the EGF/STAT3 signaling pathway.

作者信息

Lin Jiumao, Zhou Jianheng, Xu Wei, Zhong Xiaoyong, Hong Zhenfeng, Peng Jun

机构信息

Academy of Integrative Medicine Biomedical Research Center, Fujian University of Traditional Chinese Medicine, Minhou Shangjie, Fuzhou, Fujian 350122, P.R. China ; Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine, Minhou Shangjie, Fuzhou, Fujian 350122, P.R. China.

出版信息

Exp Ther Med. 2013 May;5(5):1293-1300. doi: 10.3892/etm.2013.1008. Epub 2013 Mar 15.

DOI:10.3892/etm.2013.1008
PMID:23737867
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3671788/
Abstract

Benign prostatic hyperplasia (BPH) is a pathological overgrowth of the human prostate. It may cause increased resistance to urine flow through the urethra and occasionally kidney damage, bladder stones and urinary tract infections, and therefore affect the quality of life. Qianliening capsule (QC) is a traditional Chinese formula that has been used clinically in China to treat BPH for a number of years. However, the mechanism of its anti-BPH effect remains largely unknown. We evaluated the therapeutic effect of QC in a rat model of BPH, established by the injection of testosterone following castration, and investigated the underlying molecular mechanism of action. We observed that QC treatment significantly and dose-dependently decreased the prostatic volume (PV) and prostatic index (PI; P<0.05 or P<0.01), and ameliorated the histological damage of the prostate tissue in the BPH rats. In addition, treatment with QC inhibited the phosphorylation of signal transducer and activator of transcription 3 (STAT3), as well as the expression of epidermal growth factor (EGF), epidermal growth factor receptor (EGFR), cyclin D1 and Bcl-2. Our results suggest that suppression of the EGF/STAT3 pathway may be one of the mechanisms by which QC treats BPH.

摘要

良性前列腺增生（BPH）是人类前列腺的病理性过度生长。它可能导致尿道尿流阻力增加，偶尔会引起肾损伤、膀胱结石和尿路感染，从而影响生活质量。前列宁胶囊（QC）是一种中药配方，在中国临床上用于治疗BPH已有数年。然而，其抗BPH作用的机制在很大程度上仍不清楚。我们评估了QC在去势后注射睾酮建立的BPH大鼠模型中的治疗效果，并研究了其潜在的分子作用机制。我们观察到，QC治疗显著且剂量依赖性地降低了前列腺体积（PV）和前列腺指数（PI；P<0.05或P<0.01），并改善了BPH大鼠前列腺组织的组织学损伤。此外，QC治疗抑制了信号转导和转录激活因子3（STAT3）的磷酸化，以及表皮生长因子（EGF）、表皮生长因子受体（EGFR）、细胞周期蛋白D1和Bcl-2的表达。我们的结果表明，抑制EGF/STAT3通路可能是QC治疗BPH的机制之一。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbc1/3671788/bbe72c178b5c/ETM-05-05-1293-g08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbc1/3671788/6cc132771f31/ETM-05-05-1293-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbc1/3671788/8cf75135217e/ETM-05-05-1293-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbc1/3671788/fe86fb62d43d/ETM-05-05-1293-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbc1/3671788/abb36483f998/ETM-05-05-1293-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbc1/3671788/885b59ae8e4f/ETM-05-05-1293-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbc1/3671788/75365cc307be/ETM-05-05-1293-g05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbc1/3671788/fc2dff6c39d8/ETM-05-05-1293-g06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbc1/3671788/c3cf32103b4e/ETM-05-05-1293-g07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbc1/3671788/bbe72c178b5c/ETM-05-05-1293-g08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbc1/3671788/6cc132771f31/ETM-05-05-1293-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbc1/3671788/8cf75135217e/ETM-05-05-1293-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbc1/3671788/fe86fb62d43d/ETM-05-05-1293-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbc1/3671788/abb36483f998/ETM-05-05-1293-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbc1/3671788/885b59ae8e4f/ETM-05-05-1293-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbc1/3671788/75365cc307be/ETM-05-05-1293-g05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbc1/3671788/fc2dff6c39d8/ETM-05-05-1293-g06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbc1/3671788/c3cf32103b4e/ETM-05-05-1293-g07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbc1/3671788/bbe72c178b5c/ETM-05-05-1293-g08.jpg

相似文献

1
Qianliening capsule treats benign prostatic hyperplasia via suppression of the EGF/STAT3 signaling pathway.前列宁胶囊通过抑制表皮生长因子/信号转导和转录激活因子3信号通路治疗良性前列腺增生。
Exp Ther Med. 2013 May;5(5):1293-1300. doi: 10.3892/etm.2013.1008. Epub 2013 Mar 15.
2
Qianliening capsule inhibits benign prostatic hyperplasia angiogenesis via the HIF-1α signaling pathway.前列宁胶囊通过HIF-1α信号通路抑制良性前列腺增生血管生成。
Exp Ther Med. 2014 Jul;8(1):118-124. doi: 10.3892/etm.2014.1723. Epub 2014 May 19.
3
Inhibition of the signal transducer and activator of transcription 3 signaling pathway by Qianliening capsules suppresses the growth and induces the apoptosis of human prostate cells.前列宁胶囊对信号转导与转录激活因子3信号通路的抑制作用可抑制人前列腺细胞的生长并诱导其凋亡。
Mol Med Rep. 2015 Mar;11(3):2207-14. doi: 10.3892/mmr.2014.2946. Epub 2014 Nov 13.
4
Qianliening capsule treats benign prostatic hyperplasia via induction of prostatic cell apoptosis.前列宁胶囊通过诱导前列腺细胞凋亡治疗良性前列腺增生。
Mol Med Rep. 2013 Mar;7(3):848-54. doi: 10.3892/mmr.2013.1265. Epub 2013 Jan 7.
5
Anti-proliferative effects of qianliening capsules on prostatic hyperplasia in vitro and in vivo.前列宁胶囊对前列腺增生的体内外抗增殖作用
Mol Med Rep. 2015 Aug;12(2):1699-708. doi: 10.3892/mmr.2015.3566. Epub 2015 Mar 27.
6
Canagliflozin alleviates experimentally induced benign prostate hyperplasia in a rat model: exploring potential mechanisms involving mir-128b/EGFR/EGF and JAK2/STAT3 signaling pathways through in silico and in vivo investigations.卡格列净可缓解大鼠实验性良性前列腺增生：通过计算机模拟和体内研究探索涉及 mir-128b/EGFR/EGF 和 JAK2/STAT3 信号通路的潜在机制。
Eur J Pharmacol. 2023 Oct 15;957:175993. doi: 10.1016/j.ejphar.2023.175993. Epub 2023 Aug 19.
7
miRNA Regulation Network Analysis in Qianliening Capsule Treatment of Benign Prostatic Hyperplasia.前列宁胶囊治疗良性前列腺增生的miRNA调控网络分析
Evid Based Complement Alternat Med. 2015;2015:365484. doi: 10.1155/2015/365484. Epub 2015 Jul 30.
8
Qianliening capsule () inhibits human prostate cell growth via induction of mitochondrion-dependent cell apoptosis.前列宁胶囊通过诱导线粒体依赖性细胞凋亡抑制人前列腺细胞生长。
Chin J Integr Med. 2012 Nov;18(11):824-30. doi: 10.1007/s11655-012-1264-y. Epub 2012 Oct 20.
9
Berberine Improves Benign Prostatic Hyperplasia via Suppression of 5 Alpha Reductase and Extracellular Signal-Regulated Kinase and .黄连素通过抑制5α还原酶和细胞外信号调节激酶改善良性前列腺增生。
Front Pharmacol. 2018 Jul 16;9:773. doi: 10.3389/fphar.2018.00773. eCollection 2018.
10
An inhibitory effect of Berberine from herbal Coptis chinensis Franch on rat detrusor contraction in benign prostatic hyperplasia associated with lower urinary tract symptoms.黄连中的小檗碱对伴有下尿路症状的良性前列腺增生大鼠逼尿肌收缩的抑制作用。
J Ethnopharmacol. 2021 Mar 25;268:113666. doi: 10.1016/j.jep.2020.113666. Epub 2020 Dec 7.

引用本文的文献

1
Effects of Alginate Oligosaccharide on Testosterone-Induced Benign Prostatic Hyperplasia in Orchiectomized Rats.藻寡糖对去势诱导的大鼠前列腺增生的影响。
Nutrients. 2023 Jan 29;15(3):682. doi: 10.3390/nu15030682.
2
Cleistanthins A and B Ameliorate Testosterone-Induced Benign Prostatic Hyperplasia in Castrated Rats by Regulating Apoptosis and Cell Differentiation.一叶萩碱A和B通过调节细胞凋亡和细胞分化改善去势大鼠睾酮诱导的良性前列腺增生。
Cureus. 2022 Dec 2;14(12):e32141. doi: 10.7759/cureus.32141. eCollection 2022 Dec.
3
Role of prostate stem cells and treatment strategies in benign prostate hyperplasia.

本文引用的文献

1
The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells.小分子 LLL12 抑制 STAT3 磷酸化并诱导成神经管细胞瘤和神经胶质瘤细胞凋亡。
PLoS One. 2011 Apr 19;6(4):e18820. doi: 10.1371/journal.pone.0018820.
2
Patrinia scabiosaefolia extract suppresses proliferation and promotes apoptosis by inhibiting the STAT3 pathway in human multiple myeloma cells.苍术属总状橐吾提取物通过抑制 STAT3 通路抑制人多发性骨髓瘤细胞的增殖并促进其凋亡。
Mol Med Rep. 2011 Mar-Apr;4(2):313-8. doi: 10.3892/mmr.2011.413. Epub 2011 Jan 3.
3
Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).
前列腺干细胞在良性前列腺增生中的作用及治疗策略
Am J Clin Exp Urol. 2022 Jun 15;10(3):154-169. eCollection 2022.
4
Berberine ameliorates testosterone-induced benign prostate hyperplasia in rats.小檗碱可改善睾酮诱导的大鼠良性前列腺增生。
BMC Complement Med Ther. 2021 Dec 20;21(1):301. doi: 10.1186/s12906-021-03472-2.
5
Anti-proliferative effects of qianliening capsules on prostatic hyperplasia in vitro and in vivo.前列宁胶囊对前列腺增生的体内外抗增殖作用
Mol Med Rep. 2015 Aug;12(2):1699-708. doi: 10.3892/mmr.2015.3566. Epub 2015 Mar 27.
6
Influence of Panax ginseng on Alpha-Adrenergic Receptor of Benign Prostatic Hyperplasia.人参对良性前列腺增生症α-肾上腺素能受体的影响。
Int Neurourol J. 2014 Dec;18(4):179-86. doi: 10.5213/inj.2014.18.4.179. Epub 2014 Dec 29.
7
Qianliening capsule inhibits benign prostatic hyperplasia angiogenesis via the HIF-1α signaling pathway.前列宁胶囊通过HIF-1α信号通路抑制良性前列腺增生血管生成。
Exp Ther Med. 2014 Jul;8(1):118-124. doi: 10.3892/etm.2014.1723. Epub 2014 May 19.
8
Inhibitory effect of rape pollen supercritical CO fluid extract against testosterone-induced benign prostatic hyperplasia in rats.油菜花粉超临界CO₂流体提取物对睾酮诱导的大鼠前列腺增生的抑制作用
Exp Ther Med. 2014 Jul;8(1):31-37. doi: 10.3892/etm.2014.1680. Epub 2014 Apr 14.
男性下尿路症状（LUTS）和良性前列腺增生（BPH）。
Med Clin North Am. 2011 Jan;95(1):87-100. doi: 10.1016/j.mcna.2010.08.013.
4
Benign prostatic hyperplasia.良性前列腺增生。
Clin Geriatr Med. 2010 May;26(2):223-39. doi: 10.1016/j.cger.2010.02.010.
5
[Candidate targets for research on benign prostatic hyperplasia].
Zhonghua Nan Ke Xue. 2008 Sep;14(9):771-4.
6
Reversal of benign prostate hyperplasia by selective occlusion of impaired venous drainage in the male reproductive system: novel mechanism, new treatment.通过选择性阻塞男性生殖系统中受损的静脉引流来逆转良性前列腺增生：新机制，新疗法。
Andrologia. 2008 Oct;40(5):273-81. doi: 10.1111/j.1439-0272.2008.00883.x.
7
The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics.良性前列腺增生症登记与患者调查：研究设计、方法及患者基线特征
BJU Int. 2007 Oct;100(4):813-9. doi: 10.1111/j.1464-410X.2007.07061.x.
8
An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia.良性前列腺增生患者的治疗模式与护理成本研究
Am J Manag Care. 2006 Mar;12(4 Suppl):S99-S110.
9
Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer.疾病机制：对转录信号转导子和激活子在癌症中新兴作用的见解。
Nat Clin Pract Oncol. 2005 Jun;2(6):315-24. doi: 10.1038/ncponc0195.
10
Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects.阿夫唑嗪治疗与良性前列腺增生相关的下尿路症状：疗效和不良反应的系统评价
Urology. 2005 Oct;66(4):780-8. doi: 10.1016/j.urology.2005.05.001.